Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer
The University of Texas MD Anderson Cancer Center · The University of Texas Medical Branch at Galveston
Abstract
PURPOSE: Limited data are available on long-term cardiac safety of adjuvant anthracycline chemotherapy in breast cancer patients over age 65 years. We evaluated rates and predictors of congestive heart failure (CHF) in this population. PATIENTS AND METHODS: We used the Surveillance, Epidemiology, and End Results Medicare database and included women with no history of CHF who were age 66 to 80 years and diagnosed with stage I to III breast cancer from 1992 to 2002. Cumulative rates of CHF were estimated, and multivariable Cox regression analysis was used to determine factors associated with the development of CHF. RESULTS: A total of 43,338 women were included. Anthracycline-treated women were younger, with…
Citation impact
- FWCI
- 18.90
- Percentile
- 100%
- References
- 46
Authors
5- MPMary PinderCorresponding
The University of Texas MD Anderson Cancer Center, The University of Texas Medical Branch at Galveston
- ZDZhigang Duan
The University of Texas MD Anderson Cancer Center, The University of Texas Medical Branch at Galveston
- JSJames S. Goodwin
The University of Texas MD Anderson Cancer Center, The University of Texas Medical Branch at Galveston
- GNGabriel N. Hortobágyi
The University of Texas MD Anderson Cancer Center, The University of Texas Medical Branch at Galveston
- SHSharon H. Giordano
The University of Texas MD Anderson Cancer Center, The University of Texas Medical Branch at Galveston
Topics & keywords
- Medicine
- Anthracycline
- Heart failure
- Internal medicine
- Breast cancer
- Hazard ratio
- Chemotherapy
- Population
- Good health and well-being